Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03375320
Title Cabozantinib S-malate in Treating Patients With Neuroendocrine Tumors Previously Treated With Everolimus That Are Locally Advanced, Metastatic, or Cannot Be Removed by Surgery
Recruitment Recruiting
Gender both
Phase Phase III
Variant Requirements No
Sponsors National Cancer Institute (NCI)
Indications

neuroendocrine tumor

Therapies

Cabozantinib

Age Groups: adult | senior
Covered Countries USA


No variant requirements are available.